title: An update on therapy of primary central nervous system lymphoma.
abstract: The most important advance in primary central nervous system (CNS) lymphoma treatment has been the convincing data that high-dose methotrexate-based chemotherapy regimens improve survival compared to historical controls treated with radiotherapy alone. However, the optimal treatment approach is still unclear and therapy can be associated with long-term neurotoxicity. Current research focuses on maximizing survival while minimizing neurologic sequelae.
authors.affiliation: Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. deangell@mskcc.org
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Deangelis
authors.forename: Fabio M
authors.initials: FM
authors.lastname: Iwamoto
mesh_terms: D016543:Central Nervous System Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008727:Methotrexate / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D008727:Methotrexate